Enrollment on holdAgain. This is a very good indication of the low level of confidence from the management. Normally, you don't put a hold on enrollment in open label cancer trial. By doing so, you are losing precious time. It is now easier to understand why Falardeau left the boat. No scans were published in advance of the interim results, as promised, to prove that the drug is concentrating in the tumor. So maybe there is no side-effects simply because there is no effect at all. It is not smelling good. It think that the best case scenario is now to extend the trial on a sub-set of patients. That means 40 more patients and 2 more years of trial. Worst case scenario is a simple stoppage of the trial. It seems quite obvious now that it is not working in general GBM. So all the lobsters locked in this stock must be prepared for another long waiting period. That is the reality.